Literature DB >> 16951579

Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease.

Katrin Beyer1, Jordi Humbert, Anna Ferrer, José I Lao, Cristina Carrato, Dolores López, Isidro Ferrer, Aurelio Ariza.   

Abstract

Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration. Three different isoforms (alpha-synuclein 112, 126, and 140) resulting from alternative splicing have been described so far. The present study explores alpha-synuclein 126 mRNA expression levels in the prefrontal cortex of six patients with dementia with Lewy bodies, eight patients with Lewy body variant of Alzheimer disease, eight patients with Alzheimer disease, and 10 controls. Relative alpha-synuclein 126 expression levels were determined by real-time polymerase chain reaction with competimer technology. Alpha-synuclein 126 mRNA expression was markedly decreased in the three dementias in comparison with controls, suggesting an important role of this alpha-synuclein isoform in the normal brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951579     DOI: 10.1097/01.wnr.0000224773.66904.e7

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

Review 1.  Biochemical premotor biomarkers for Parkinson's disease.

Authors:  Brit Mollenhauer; Jing Zhang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

2.  Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons.

Authors:  Mong-Lin Yang; Linda Hasadsri; Wendy S Woods; Julia M George
Journal:  Mol Neurodegener       Date:  2010-02-09       Impact factor: 14.195

Review 3.  Structural variants in SNCA gene and the implication to synucleinopathies.

Authors:  Ornit Chiba-Falek
Journal:  Curr Opin Genet Dev       Date:  2017-03-02       Impact factor: 5.578

4.  New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.

Authors:  Katrin Beyer; Ana M Munoz-Marmol; Carolina Sanz; Ruth Marginet-Flinch; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2011-12-29       Impact factor: 2.660

5.  Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Authors:  Jesse R McLean; Penelope J Hallett; Oliver Cooper; Michael Stanley; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

6.  Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases.

Authors:  Katrin Beyer; Montserrat Domingo-Sábat; José I Lao; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2007-10-23       Impact factor: 2.660

Review 7.  Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.

Authors:  Adrien W Schmid; Bruno Fauvet; Marc Moniatte; Hilal A Lashuel
Journal:  Mol Cell Proteomics       Date:  2013-08-21       Impact factor: 5.911

8.  Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.

Authors:  Katrin Beyer; Montserrat Domingo-Sàbat; Jordi Humbert; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2008-03-12       Impact factor: 2.660

Review 9.  Up-regulation of SNCA gene expression: implications to synucleinopathies.

Authors:  L Tagliafierro; O Chiba-Falek
Journal:  Neurogenetics       Date:  2016-03-07       Impact factor: 2.660

Review 10.  Molecular pathology of Lewy body diseases.

Authors:  Katrin Beyer; Montserrat Domingo-Sàbat; Aurelio Ariza
Journal:  Int J Mol Sci       Date:  2009-02-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.